In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Punjab❤️Call girls in Mohali ☎️7435815124☎️ Call Girl service in Mohali☎️ Moh...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st Open Webinar
1. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A TRUST-CENTRIC HEALTHCARE JOURNEY
24
NOV
2
DEC
2. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A T R U S T - C E N T R I C H E A L T H C A R E J O U R N E Y
INTRO
Ly n n Wa n g ( J o h n s o n & J o h n s o n )
P h a r m a L e d g e r D o m a i n L e a d S u p p l y C h a i n
24
NOV
2
DEC
3. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
P H A R M A L E D G E R I N A N U T S H E L L
Who? PharmaLedger partners comprises of pharmaceutical
companies, hospitals, universities, patient organizations, tech
companies... building an ecosystem!
Why? To empower patients, increase digital trust among
healthcare stakeholders, support medicine drug traceability and
data privacy, and build a new culture of collaboration in
healthcare.
What? A scalable blockchain based platform validated
through reference use cases in supply chain, clinical trials and
health data that will serve trendsetters for the industry, enabling
early adopters.
How? Pharmaledger will design, validate and provide agile
delivery of innovative blockchain enabled healthcare applications
across the industry, from manufacturers to patients; while creating
an innovative governance approach for sustainability.
Duration
3 years
Jan 20 – Dec 22
Consortium
29 partners
Budget
22 million
Euros
Focus Areas
Supply Chain,
Clinical Trial, and
Health Data
5. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A TRU ST- C E N T R IC HEALT H C A R E J OURNE Y
TOPIC 1 | Clinical Supply Tr aceability
Fr ancesco Spoto (Nov artis )
Chad Sklodosky (Pfiz er)
24
NOV
2
DEC
With the contribution of GSK, MSD,
Onorach, OPBG and RomSoft
10. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A TRU ST- C E N T R IC HEALT H C A R E J OURNE Y
TOPIC 2 | Finished Goods Tr aceability
Dr. Jan Wor tmann (Bay er)
Ber nhar d Salb (Roc he)
24
NOV
2
DEC
With the contribution of abbvie, GSK, J&J,
MSD, Novartis, Pfizer, PDMFC & Romsoft
15. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A TRU ST- C E N T R IC HEALT H C A R E J OURNE Y
TOPIC 3 | ePI | elec tronic produc t information
Patr ick Maher (Nov artis )
Ken Thur sby (MSD)
24
NOV
2
DEC
With the contribution of Democritus University of Thrace, EKON, GSK,
J&J, Novartis, PDMFC, Pfizer, MSD, Novo Nordisk, Romsoft, UCB,
Universidad Politécnica de Madrid
24. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
Open Webinar
A Tr ust - Centr ic Healthc are J ourney
TOPIC 4 | Anti - Counter feiting
Daniel Fr itz (Nov artis )
Alber to López (Imprensa Nacional Casa da Moeda)
24
NOV
2
DEC
With the contribution of Bayer,
NovoNordisk, PDMFC, TVS and GSK
32. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
T H A N K Y O U